The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 17, 2020
Filed:
Mar. 22, 2018
The Johns Hopkins University, Baltimore, MD (US);
Duke University, Durham, NC (US);
Bert Vogelstein, Baltimore, MD (US);
Kenneth W. Kinzler, Baltimore, MD (US);
D. Williams Parsons, Bellaire, TX (US);
Xiaosong Zhang, San Francisco, CA (US);
Jimmy Cheng-Ho Lin, Baltimore, MD (US);
Rebecca J. Leary, Cambridge, MA (US);
Philipp Angenendt, Baltimore, MD (US);
Nickolas Papadopoulos, Towson, MD (US);
Victor Velculescu, Dayton, MD (US);
Giovanni Parmigiani, Baltimore, MD (US);
Rachel Karchin, Towson, MD (US);
Sian Jones, Baltimore, MD (US);
Hai Yan, Durham, MD (US);
Darell Bigner, Mebane, NC (US);
Chien-Tsun Kuan, Cary, NC (US);
Gregory J. Riggins, White Hall, MD (US);
The Johns Hopkins University, Baltimore, MD (US);
Duke University, Durham, NC (US);
Abstract
We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in gliblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.